<p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 獲取免費報告) 的股價在週四的午盤交易中上漲了 4.4%。該股最高交易價格為 14.01 美元，最後交易價格為 14.04 美元。交易期間大約有 449,627 股成交，較日均成交量 2,224,287 股下降了 80%。該股此前收盤價為 13.45 美元。</p>
<p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票研究分析師對 SNDX 股票發佈了報告。花旗集團將 Syndax Pharmaceuticals 的目標股價從 46.00 美元上調至 51.00 美元，並在 8 月 5 日的研究報告中給予該公司 &#34;買入&#34; 評級。BTIG Research 將 Syndax Pharmaceuticals 的目標股價從 43.00 美元上調至 56.00 美元，並在 8 月 5 日的研究報告中給予該公司 &#34;買入&#34; 評級。加拿大豐業銀行將 Syndax Pharmaceuticals 的目標股價從 16.00 美元上調至 17.00 美元，並在 5 月 6 日的研究報告中給予該公司 &#34;行業表現&#34; 評級。瑞銀集團將 Syndax Pharmaceuticals 的目標股價從 37.00 美元下調至 35.00 美元，並在 7 月 15 日的研究報告中給予該公司 &#34;買入&#34; 評級。最後，古根海姆在 5 月 6 日的研究報告中重申了 &#34;買入&#34; 評級，並將 Syndax Pharmaceuticals 的目標股價設定為 32.00 美元。一位分析師給予該股 &#34;賣出&#34; 評級，一位給予 &#34;持有&#34; 評級，十位給予 &#34;買入&#34; 評級，一位給予 &#34;強力買入&#34; 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 &#34;適度買入&#34;，共識目標價為 36.91 美元。</p>
<p><strong>查看我們最新的 SNDX 股票分析</strong></p>
<h2>Syndax Pharmaceuticals 股價上漲 6.6%</h2>
<p>該股市值為 12.4 億美元，市盈率為 -3.69，貝塔值為 0.74。該公司的流動比率為 4.71，速動比率為 4.55，債務與股本比率為 2.06。該股的 50 日移動平均價格為 10.20 美元，200 日移動平均價格為 11.88 美元。</p>
<p>Syndax Pharmaceuticals (NASDAQ:SNDX - 獲取免費報告) 最近在 8 月 4 日發佈了季度財報。該公司報告季度每股收益為（0.83 美元），超出分析師共識預期的（1.01 美元）0.18 美元。Syndax Pharmaceuticals 的淨利潤率為 -428.48%，股本回報率為 -130.47%。該公司在本季度的收入為 3,796 萬美元，而分析師預期為 2,664 萬美元。在去年同期，該公司每股收益為（0.80 美元）。與去年同期相比，該公司的收入增長了 984.5%。股票研究分析師預測 Syndax Pharmaceuticals, Inc. 本年度將發佈 -3.72 美元的每股收益。</p>
<h2>內部買賣情況</h2>
<p>在相關消息中，首席執行官 Michael A. Metzger 於 7 月 16 日星期三出售了 7,534 股公司股票。股票以平均價格 9.29 美元出售，總交易額為 69,990.86 美元。出售完成後，首席執行官直接持有公司 298,661 股，價值 2,774,560.69 美元。這代表其持股減少了 2.46%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。4.10% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 Syndax Pharmaceuticals 的看法</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了在 SNDX 的持股。Soleus Capital Management L.P. 在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P. 目前持有該公司 2,492,000 股股票，價值 32,944,000 美元，在此期間又購買了 1,401,016 股。Stempoint Capital LP 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 48.4%。Stempoint Capital LP 目前持有該公司 2,372,634 股股票，價值 22,220,000 美元，在此期間又購買了 774,040 股。富蘭克林資源公司在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 14.5%。富蘭克林資源公司目前持有該公司 2,359,677 股股票，價值 22,098,000 美元，在此期間又購買了 298,272 股。Geode Capital Management LLC 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 1.3%。Geode Capital Management LLC 目前持有該公司 2,049,350 股股票，價值 19,195,000 美元，在此期間又購買了 26,365 股。最後，Qube Research &amp; Technologies Ltd 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 99.5%。Qube Research &amp; Technologies Ltd 目前持有該公司 1,665,916 股股票，價值 15,601,000 美元，在此期間又購買了 831,067 股。</p>
<h2>關於 Syndax Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的小分子抑制劑，針對 KMT2A 重排的急性白血病和實體腫瘤的 menin-MLL 結合相互作用；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Syndax Pharmaceuticals 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>深度低估，Micron Technologies 股票未考慮 AI</li>
<li>3 只醫療保健分紅股票值得購買</li>
<li>世紀鋁業：工業復甦的優質股票</li>
<li>如何投資小型股</li>
<li>思科系統：唯一需要擁有的 AI 股票收入投資者</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
<p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Syndax Pharmaceuticals 並不在名單上。</p>
<p>雖然 Syndax Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Syndax制藥

<p>Syndax 製藥（NASDAQ:SNDX）在午盤交易中股價上漲 4.4%，達到 14.04 美元。分析師們發佈了各種評級，花旗集團和 BTIG 研究大幅上調了目標價格。該公司報告的季度每股收益為（-0.83 美元），超出預期，營收同比增長 984.5%。內部交易活動包括首席執行官 Michael A. Metzger 出售股份，機構投資者也增加了對公司的持股。該股票的市值為 12.4 億美元，市場共識評級為 “適度買入”</p>

<p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report)'s share price was up 4.4% during mid-day trading on Thursday . The stock traded as high as $14.01 and last traded at $14.04. Approximately 449,627 shares traded hands during trading, a decline of 80% from the average daily volume of 2,224,287 shares. The stock had previously closed at $13.45.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 獲取免費報告) 的股價在週四的午盤交易中上漲了 4.4%。該股最高交易價格為 14.01 美元，最後交易價格為 14.04 美元。交易期間大約有 449,627 股成交，較日均成交量 2,224,287 股下降了 80%。該股此前收盤價為 13.45 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities research analysts have issued reports on SNDX shares. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, August 5th. BTIG Research lifted their target price on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, August 5th. Scotiabank lifted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a &#34;sector perform&#34; rating in a research report on Tuesday, May 6th. UBS Group dropped their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, July 15th. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $36.91.</p>
<div class="lb-trans"><p>幾位股票研究分析師對 SNDX 股票發佈了報告。花旗集團將 Syndax Pharmaceuticals 的目標股價從 46.00 美元上調至 51.00 美元，並在 8 月 5 日的研究報告中給予該公司 &#34;買入&#34; 評級。BTIG Research 將 Syndax Pharmaceuticals 的目標股價從 43.00 美元上調至 56.00 美元，並在 8 月 5 日的研究報告中給予該公司 &#34;買入&#34; 評級。加拿大豐業銀行將 Syndax Pharmaceuticals 的目標股價從 16.00 美元上調至 17.00 美元，並在 5 月 6 日的研究報告中給予該公司 &#34;行業表現&#34; 評級。瑞銀集團將 Syndax Pharmaceuticals 的目標股價從 37.00 美元下調至 35.00 美元，並在 7 月 15 日的研究報告中給予該公司 &#34;買入&#34; 評級。最後，古根海姆在 5 月 6 日的研究報告中重申了 &#34;買入&#34; 評級，並將 Syndax Pharmaceuticals 的目標股價設定為 32.00 美元。一位分析師給予該股 &#34;賣出&#34; 評級，一位給予 &#34;持有&#34; 評級，十位給予 &#34;買入&#34; 評級，一位給予 &#34;強力買入&#34; 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 &#34;適度買入&#34;，共識目標價為 36.91 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on SNDX</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 SNDX 股票分析</strong></p>
</div><h2>Syndax Pharmaceuticals Trading Up 6.6%</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股價上漲 6.6%</h2>
</div><p>The stock has a market capitalization of $1.24 billion, a P/E ratio of -3.69 and a beta of 0.74. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The stock's fifty day moving average price is $10.20 and its two-hundred day moving average price is $11.88.</p>
<div class="lb-trans"><p>該股市值為 12.4 億美元，市盈率為 -3.69，貝塔值為 0.74。該公司的流動比率為 4.71，速動比率為 4.55，債務與股本比率為 2.06。該股的 50 日移動平均價格為 10.20 美元，200 日移動平均價格為 11.88 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company had revenue of $37.96 million during the quarter, compared to analyst estimates of $26.64 million. During the same period in the prior year, the business posted ($0.80) EPS. The firm's revenue was up 984.5% compared to the same quarter last year. Equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (NASDAQ:SNDX - 獲取免費報告) 最近在 8 月 4 日發佈了季度財報。該公司報告季度每股收益為（0.83 美元），超出分析師共識預期的（1.01 美元）0.18 美元。Syndax Pharmaceuticals 的淨利潤率為 -428.48%，股本回報率為 -130.47%。該公司在本季度的收入為 3,796 萬美元，而分析師預期為 2,664 萬美元。在去年同期，該公司每股收益為（0.80 美元）。與去年同期相比，該公司的收入增長了 984.5%。股票研究分析師預測 Syndax Pharmaceuticals, Inc. 本年度將發佈 -3.72 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In related news, CEO Michael A. Metzger sold 7,534 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total transaction of $69,990.86. Following the completion of the sale, the chief executive officer directly owned 298,661 shares in the company, valued at $2,774,560.69. This represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Michael A. Metzger 於 7 月 16 日星期三出售了 7,534 股公司股票。股票以平均價格 9.29 美元出售，總交易額為 69,990.86 美元。出售完成後，首席執行官直接持有公司 298,661 股，價值 2,774,560.69 美元。這代表其持股減少了 2.46%。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。4.10% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Syndax Pharmaceuticals 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Soleus Capital Management L.P. lifted its position in shares of Syndax Pharmaceuticals by 128.4% in the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after purchasing an additional 1,401,016 shares during the period. Stempoint Capital LP lifted its position in shares of Syndax Pharmaceuticals by 48.4% in the 2nd quarter. Stempoint Capital LP now owns 2,372,634 shares of the company's stock worth $22,220,000 after purchasing an additional 774,040 shares during the period. Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 14.5% in the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares during the period. Geode Capital Management LLC lifted its position in shares of Syndax Pharmaceuticals by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after purchasing an additional 26,365 shares during the period. Finally, Qube Research &amp; Technologies Ltd lifted its position in shares of Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 1,665,916 shares of the company's stock worth $15,601,000 after purchasing an additional 831,067 shares during the period.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了在 SNDX 的持股。Soleus Capital Management L.P. 在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P. 目前持有該公司 2,492,000 股股票，價值 32,944,000 美元，在此期間又購買了 1,401,016 股。Stempoint Capital LP 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 48.4%。Stempoint Capital LP 目前持有該公司 2,372,634 股股票，價值 22,220,000 美元，在此期間又購買了 774,040 股。富蘭克林資源公司在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 14.5%。富蘭克林資源公司目前持有該公司 2,359,677 股股票，價值 22,098,000 美元，在此期間又購買了 298,272 股。Geode Capital Management LLC 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 1.3%。Geode Capital Management LLC 目前持有該公司 2,049,350 股股票，價值 19,195,000 美元，在此期間又購買了 26,365 股。最後，Qube Research &amp; Technologies Ltd 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 99.5%。Qube Research &amp; Technologies Ltd 目前持有該公司 1,665,916 股股票，價值 15,601,000 美元，在此期間又購買了 831,067 股。</p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Syndax Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的小分子抑制劑，針對 KMT2A 重排的急性白血病和實體腫瘤的 menin-MLL 結合相互作用；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AI</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Century Aluminum: A Premier Stock for the Industrial Resurgence</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Cisco Systems: The Only AI Stock Income Investors Need to Own</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Syndax Pharmaceuticals 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>深度低估，Micron Technologies 股票未考慮 AI</li>
<li>3 只醫療保健分紅股票值得購買</li>
<li>世紀鋁業：工業復甦的優質股票</li>
<li>如何投資小型股</li>
<li>思科系統：唯一需要擁有的 AI 股票收入投資者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Syndax Pharmaceuticals 並不在名單上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Syndax Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Syndax 製藥（NASDAQ:SNDX）股價上漲 4.4% - 現在是買入的好時機嗎？